Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$93.06

0.18 (0.19%)

, PFE

Pfizer

$35.86

0.35 (0.99%)

08:32
05/15/18
05/15
08:32
05/15/18
08:32

Sarepta price target raised to $121 from $88 at Leerink

Leerink analyst Joseph Schwartz raised his price target for Sarepta (SRPT) to $121 from $88, while reiterating an Outperform rating on the shares. The analyst notes that Sarepta is one of three companies developing microdystrophin gene therapy for Duchenne muscular dystrophy, in competition with Pfizer (PFE) who acquired Bamboo, and Solid Biosciences (SLDB). With Solid's clinical hold still in place, Sarepta could potentially be first-to-market, and is expected to report the first clinical data for a micro-dystrophin candidate at their R&D day on June 19, he adds.

SRPT

Sarepta

$93.06

0.18 (0.19%)

PFE

Pfizer

$35.86

0.35 (0.99%)

SLDB

Solid Biosciences

$21.71

-0.79 (-3.51%)

  • 16

    May

  • 20

    May

  • 05

    Jun

SRPT Sarepta
$93.06

0.18 (0.19%)

05/11/18
LEHM
05/11/18
UPGRADE
Target $107
LEHM
Overweight
Sarepta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Gena Wang upgraded Sarepta Therapeutics to Overweight and raised her price target for the shares to $107 from $55. The "good safety profile" of the company's PMO franchise could replace its "suboptimal" PMO franchise, Wang tells investors in a research note. The analyst, while seeing a limited opportunity in Europe for Exondys 51, believes Sarepta's microdystrophin program has a "reasonable chance" to show promising clinical activity.
05/10/18
NOMU
05/10/18
NO CHANGE
Target $131
NOMU
Buy
Nomura recommends owning Sarepta for 'second dose' of upside
An overlooked takeaway from Sarepta Therapeutics' earnings call is the company highlighting its "aggressive and ambitious" plans to progress its gene therapy program, Nomura Instinet analyst Christopher Marai tells investors in a research note. He recommends recommend owning the stock for a "second dose of potential upside." The analyst has a Buy rating on Sarepta with a $131 price target.
05/07/18
NEED
05/07/18
NO CHANGE
Target $109
NEED
Buy
Sarepta price target raised to $109 from $75 at Needham
Needham analyst Chad Messer raised his price target on Sarepta to $109 and kept his Buy rating after the company's in-line Q1 results. Messer cites Sarepta's announcing an R&D presentation on June 19th to discuss its "growing pipeline", adding that the company had already promised "at least 2 patients worth of safety and gene expression data from the ongoing microdystrophin gene therapy program". The analyst expects Sarepta stock to reflect investor optimism typically given to early data from gene therapy companies.
05/07/18
HCWC
05/07/18
NO CHANGE
Target $96
HCWC
Buy
Sarepta price target raised to $96 from $90 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Sarepta Therapeutics to $96 and keeps a Buy rating on the shares. The Myonexus alliance augments Sarepta's pipeline with three clinical stage gene therapy programs along with two preclinical efforts, "significantly expanding" its focus and exposure to gene therapy and genetic medicine, Chattopadhyay tells investors in a research note.
PFE Pfizer
$35.86

0.35 (0.99%)

04/16/18
NORL
04/16/18
NO CHANGE
NORL
Outperform
Pfizer appears to be BioLife Solutions customer, says Northland
Northland analyst Suraj Kalia believes Pfizer (PFE) has never publicly announced itself as a customer of BioLife Solutions (BLFS), but a link to a presentation apparently made at the AAPS conference seems to highlight Pfizer' use of BioLife's CryoStor cryopreservation medium in its CAR-T program. Kalie noted this is the first time he has learned of Pfizer being a customer and of the use of BioLife's CryoStor being used in allogeneic CAR-T applications, both of which he finds interesting. Kalia has an Outperform rating on BioLife.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/19/18
04/19/18
NO CHANGE

BTIG says Allergan may be interested in Shire after insufficient Takeda offers
BTIG analyst Timothy Chiang noted that Shire (SHPG) is trading higher after news that at least one other company other than Takeda (TKPYY) is interested in acquiring Shire, and naming Allergan (AGN) as one of those possible suitors. Chiang also believes that other companies, such as Pfizer (PFE), could entering into the bidding for Shire. BTIG maintained a Buy rating and $195 price target on Shire shares.
SLDB Solid Biosciences
$21.71

-0.79 (-3.51%)

05/10/18
LEER
05/10/18
NO CHANGE
Target $28
LEER
Outperform
Solid Biosciences price target raised to $28 from $14 at Leerink
Leerink analyst Joseph Schwartz raised his price target on Solid Biosciences to $28 from $14 after he updated his model to reflect Q1 results and increased his probability of success estimate for SGT-001 to 30% from 20%. His probability of success estimate for SB-001 is unchanged at 20%, he noted. Schwartz keeps an Outperform rating on Solid Biosciences shares.
03/15/18
03/15/18
NO CHANGE

Sarepta lead solidified with Solid clinical hold, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says Sarepta Therapeutics' (SRPT) lead in developing a gene therapy for Duchenne muscular dystrophy is potentially solidified after Solid Biosciences' (SLDB) Phase 1/2 clinical program was placed on clinical hold. Based on the differences between Sarepta's and Solid's vectors and the evolving safety profiles of the two competing approaches, the analyst would be a buyer of Sarepta's stock "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He keeps a Buy rating on Sarepta shares with a $92 price target.
04/02/18
LEER
04/02/18
NO CHANGE
Target $14
LEER
Outperform
Solid Biosciences price target lowered to $14 from $36 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Solid Biosciences to $14 from $36 saying that while it was able to withstand several initial concerns that were addressed when the company was going public - including preclinical safety, a board member resignation, manufacturing issues -, Solid Biosciences' recent clinical hold announcement was "the straw that broke the camel's back" resulting in a massive selloff. The analyst reiterates an Outperform rating on the shares.
03/15/18
LEER
03/15/18
NO CHANGE
LEER
Outperform
Solid Biosciences selloff on clinical hold news may be premature, says Leerink
Leerink analyst Joseph Schwartz says Solid Biosciences' disclosure of a clinical hold on Phase 1/2 IGNITE DMD trial comes as a surprise. However, the analyst believes it is too early to throw in the towel on SGT-001. In fact, a "knee-jerk reaction" may present an attractive buying opportunity for investors due to small sample size, a lack of other noteworthy adverse effects, and patients positive recovery since the incident. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:04
11/15/18
11/15
18:04
11/15/18
18:04
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

18:01
11/15/18
11/15
18:01
11/15/18
18:01
Hot Stocks
Nvidia CEO says came into Q3 with excess inventory from crypto overhang »

Says the decline in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

TDW

Tidewater

$25.71

1.22 (4.98%)

17:52
11/15/18
11/15
17:52
11/15/18
17:52
Hot Stocks
Tidewater CFO Quinn Fanning steps down, succeeded by Gulfmark CEO Quintin Kneen »

Tidewater CFO Quinn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

17:52
11/15/18
11/15
17:52
11/15/18
17:52
Hot Stocks
Nvidia CEO expects to continue seeing demand in data center business »

Says because CPUs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

ISR

IsoRay

$0.39

-0.0051 (-1.29%)

17:51
11/15/18
11/15
17:51
11/15/18
17:51
Hot Stocks
IsoRay director Philip Vitale buys 30K shares of company stock »

IsoRay director Philip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$202.65

5.43 (2.75%)

17:50
11/15/18
11/15
17:50
11/15/18
17:50
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia sees FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

NVDA

Nvidia

$202.65

5.43 (2.75%)

17:49
11/15/18
11/15
17:49
11/15/18
17:49
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia says its outlook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

ADES

Advanced Emissions

$9.71

-0.17 (-1.72%)

17:40
11/15/18
11/15
17:40
11/15/18
17:40
Hot Stocks
Breaking Hot Stocks news story on Advanced Emissions »

Advanced Emissions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMT

America's Car-Mart

$71.90

-0.495 (-0.68%)

17:38
11/15/18
11/15
17:38
11/15/18
17:38
Earnings
America's Car-Mart reports Q2 EPS $1.58 vs. 79c last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NVDA

Nvidia

$202.65

5.43 (2.75%)

17:35
11/15/18
11/15
17:35
11/15/18
17:35
Hot Stocks
Nvidia says its competitive position is as strong as ever »

Says the company remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

HRB

H&R Block

$28.18

-0.07 (-0.25%)

17:35
11/15/18
11/15
17:35
11/15/18
17:35
Syndicate
Breaking Syndicate news story on H&R Block »

H&R Block files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEL

American Equity

$34.34

0.105 (0.31%)

17:26
11/15/18
11/15
17:26
11/15/18
17:26
Hot Stocks
American Equity raises annual dividend 8% to 28c per share »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXGN

AxoGen

$32.97

0.78 (2.42%)

17:26
11/15/18
11/15
17:26
11/15/18
17:26
Hot Stocks
AxoGen directorGregory Freitag sells 20K shares of company stock »

AxoGen director Gregory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

NI

NiSource

$25.30

-0.3 (-1.17%)

17:25
11/15/18
11/15
17:25
11/15/18
17:25
Hot Stocks
NiSource says 'thoroughly reviewing' NTSB safety recommendation report »

NiSource released the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVMT

Dell Technologies

$105.06

-0.69 (-0.65%)

17:25
11/15/18
11/15
17:25
11/15/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Dell Technologies »

Dodge & Cox reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GNBC

Green Bancorp

$18.71

0.53 (2.92%)

, VBTX

Veritex

$23.60

0.66 (2.88%)

17:25
11/15/18
11/15
17:25
11/15/18
17:25
Conference/Events
Veritex to host special shareholder meeting »

Special Shareholder…

GNBC

Green Bancorp

$18.71

0.53 (2.92%)

VBTX

Veritex

$23.60

0.66 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

HP

Helmerich & Payne

$60.05

1.75 (3.00%)

17:24
11/15/18
11/15
17:24
11/15/18
17:24
Hot Stocks
Breaking Hot Stocks news story on Helmerich & Payne »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

HP

Helmerich & Payne

$60.05

1.75 (3.00%)

17:23
11/15/18
11/15
17:23
11/15/18
17:23
Earnings
Helmerich & Payne reports Q4 EPS 2c, may not compare to consensus 18c »

Reports Q4 revenue $697M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

AKBA

Akebia

$7.91

0.44 (5.89%)

, KERX

Keryx

$2.93

0.17 (6.16%)

17:19
11/15/18
11/15
17:19
11/15/18
17:19
Hot Stocks
Akebia and Keryx announce chairperson for combined company »

Akebia Therapeutics…

AKBA

Akebia

$7.91

0.44 (5.89%)

KERX

Keryx

$2.93

0.17 (6.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

  • 11

    Dec

RLH

Red Lion Hotels

$8.75

0.9 (11.47%)

17:16
11/15/18
11/15
17:16
11/15/18
17:16
Syndicate
Breaking Syndicate news story on Red Lion Hotels »

Red Lion Hotels files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ADES

Advanced Emissions

$9.71

-0.17 (-1.72%)

17:16
11/15/18
11/15
17:16
11/15/18
17:16
Hot Stocks
Advanced Emissions to acquire ADA Carbon Solutions for $75M »

Advanced Emissions has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$35.03

1.44 (4.29%)

17:14
11/15/18
11/15
17:14
11/15/18
17:14
Hot Stocks
Applied Materials falls further in late trading, now down 9% »

Shares of Applied …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

LMT

Lockheed Martin

$305.48

2.23 (0.74%)

17:09
11/15/18
11/15
17:09
11/15/18
17:09
Hot Stocks
Lockheed Martin awarded $172.15M Air Force contract for LRASMs »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$32.97

0.65 (2.01%)

17:09
11/15/18
11/15
17:09
11/15/18
17:09
Hot Stocks
Yelp officer Alan Ramsay sells 5,000 shares of company stock »

Yelp officer Alan Ramsay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTG

Heritage Insurance

$16.10

0.28 (1.77%)

17:09
11/15/18
11/15
17:09
11/15/18
17:09
Hot Stocks
Heritage Insurance CEO acquires 62,142 common shares for $1M »

Heritage Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.